53 documents on Dr. Reddy's Laboratories Ltd.: 12 annual reports, 4 investor presentations, 22 analyst and investor calls: notices, recordings, transcripts, 15 press releases. Annual reports from the exchange's archive; the rest from twelve months of Regulation 30 announcements, in the exchange's own categories, each linked to the PDF the company filed.
Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated August 01, 2026, titled "Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015".
Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated July 23, 2026, titled "Intimation of Earnings call recording".
Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated Jun 13, 2026, titled "Dr. Reddy s announces the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States.".
Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Dr. Reddy's Laboratories to Ring the Closing Bell® at the New York Stock Exchange.
Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated May 15, 2026, titled "Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada".
Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated March 21, 2026, titled "Dr. Reddy s Laboratories announces launch of India s first DCGI-approved Semaglutide injection Obeda® for Type 2 Diabetes.".
Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated February 18, 2026, titled "Dr. Reddy's forays into Hormone Replacement Therapy segment with acquisition of Progynova® and Cyclo- Progynova® in India".
Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated January 14, 2026, titled "Dr. Reddy s announces the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the generic equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.".
Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated December 12, 2025, titled "Dr. Reddy s Laboratories announces Science-Based Net Zero Climate Targets".
Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated November 24, 2025, titled "Dr. Reddy s receives European Commission approval for AVT03 (denosumab), a proposed Biosimilar of Prolia® and Xgeva®".
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.